Core Viewpoint - The private equity market is experiencing a significant rebound, with a record number of private securities fund products being registered in July 2025, driven by improved investor confidence and strong performance of quantitative strategies [2][3]. Group 1: Market Overview - In July 2025, a total of 1,298 private securities fund products were registered, marking an 18.00% month-on-month increase and the highest level in nearly 27 months [2]. - Year-to-date, the number of registered private securities fund products reached 6,759, reflecting a year-on-year increase of 61.39% [2]. - The A-share market's positive performance, with the Shanghai Composite Index surpassing the 3,600-point mark, has significantly boosted investor participation and confidence [2]. Group 2: Strategy Performance - Stock strategies dominated the market, with 887 products registered in July, accounting for 68.34% of the total, and a month-on-month growth of 24.58% [3][4]. - Multi-asset strategies are gaining traction, with 162 products registered, representing 12.48% of the total, and a month-on-month increase of 5.88% [3][4]. - The registration of futures and derivatives strategies remained stable, with 125 products registered, accounting for 9.63% of the total [4]. Group 3: Quantitative Products - Quantitative products saw a significant increase, with 620 products registered in July, representing 47.77% of the total, and a month-on-month growth of 19.00% [5][6]. - Year-to-date, the number of registered quantitative products reached 3,081, accounting for 45.58% of the total, with a year-on-year increase of 77.68% [5]. Group 4: Leading Firms - In July, 676 private equity firms registered products, with 48 firms managing over 10 billion, indicating a strong presence of large-scale private equity firms [9][10]. - Leading firms in the quantitative space include Kuande, Mingfa, and Century Frontier, each managing over 100 billion and focusing primarily on index enhancement strategies [10][11].

本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看 详情 ） 巨量均衡基金 成立于2021年6月，是以科技与科学计算来驱动投资的科技型对冲基金公司，团队有18年以上的历史量化积累的底蕴， 在机构里为投资人持续带来过亮眼的收益表现。目前规模约4亿，公司人员12人。创始人程志田先生有18年以上大型机构直接的量化投 研经验，原公募基金行业头部量化团队负责人，个人管理公募基金70亿，直管部门历史最高300亿主动管理规模（公募+专户）。 私募排排网数据显示，截至2025年6月底： 在小而美量化私募基金半年度业绩排名中， 巨量均衡基金近半年平均收益达***%，位列Top10。 （ 点击查看收益详情 ） 巨量均衡基金近半年平均收益***%， 位列新锐量化私募半年度收益Top5、深圳地区私募排名Top20。 （ 点击查看收益详情 ） 巨量均衡团队一直保持持续学习与高速成长，在将来的岁月里，将会持续与客户相伴，力争为客户带来持续长久的业绩回报。 （点此查看 巨量均衡基金观点：A股站上3500点，量化指增还能上车？ ） 巨量均衡基金简介 程志田 100% 100% 程志田 数据来源：协会公示信息 发展历程 2021年6月 · ...

Core Viewpoint - Lin Yuan Investment has been increasingly active in A-share market, participating in multiple company research activities and IPOs, indicating a strategic focus on essential consumer goods and biopharmaceuticals [2][5][8]. Group 1: Research Activities - Lin Yuan Investment participated in 8 research activities involving 7 A-share listed companies by the end of July 2025, a significant increase from only 2 companies in the same period last year [2][5]. - The sectors of the researched companies include 2 biopharmaceuticals, 2 automotive industry companies, and 1 each from food, semiconductor, and new materials, showing a preference for medical and essential consumer stocks [5]. - The two biopharmaceutical companies researched focus on surgical medical devices and the development of innovative drugs for cancer and autoimmune diseases [5][6]. Group 2: Market Performance - The two biopharmaceutical companies have shown strong market performance, with one increasing over 18% and the other by 44.31% year-to-date as of August 5, 2025 [6]. - Among the 7 researched companies, Feilong Co., a veteran automotive parts manufacturer, has the best performance with a year-to-date increase of 57.08% [6]. - Feilong Co. has been actively engaging with investors, receiving 153 institutional research visits, including from notable private equity firms [6]. Group 3: IPO Participation - Lin Yuan Investment has participated in 41 IPOs this year, with the highest first-day return reaching 606.83% for Jiangnan New Materials [8][9]. - The average first-day increase for the 41 IPOs Lin Yuan participated in is over 220%, reflecting a strong market for new listings [9]. - The participation in IPOs has been driven by a tightening IPO environment, with a significant drop in the number of new listings, making new stocks more scarce and attractive [8].

Market Overview - In July, A-shares experienced a strong upward trend, with the Shanghai Composite Index rising by 3.74%, the Shenzhen Component Index by 5.20%, and the ChiNext Index by 8.14% [1] - The total market turnover remained above 1.5 trillion, indicating active trading, while the financing balance climbed to 1.9 trillion by late July, reflecting a positive market sentiment [1] Private Equity Performance - A total of 379 private equity products reached historical highs in July, representing 71.64% of the total number of billion-yuan private equity products with performance data available for nearly one year [1] - Among these, 289 were quantitative products and 90 were non-quantitative, with stock strategy products being the most prevalent, accounting for approximately 83.38% [1] Top Performing Private Equity Firms - 28 billion-yuan private equity firms had all their products reach historical highs in July, with 18 firms having more than three products achieving this milestone [2] - Notable firms include Junzhijian Investment, Rido Investment, and Tianyan Capital, with a significant number of their products achieving new highs [2] Performance Rankings - The average returns for private equity firms from January to July were led by Wobo Investment, Abama Investment, Tianyan Capital, Rido Investment, and Ningbo Huanfang Quantitative [3] - Over the past three years, the top five firms based on average returns were Junzhijian Investment, Rido Investment, Abama Investment, Tianyan Capital, and Maoyuan Quantitative [3] Notable Products - The top products achieving historical highs in the past year included those from Heiyi Asset, Longqi Technology, and Rido Investment, with the threshold for the top 20 products exceeding a certain percentage [7] - The leading product was "Heiyi Wind 2 B Class" from Heiyi Asset, with a recent scale of approximately *** million and nearly ***% return over the past year [9] Long-term Performance - Over the past five years, the top products were from Rido Investment, Fusheng Asset, and Jiukun Investment, with Rido Investment holding three of the top five positions [14] - The champion product was "Rido Qian Niu Value No. 1" from Rido Investment, with a recent scale of approximately *** billion and over ***% return in the past five years [16] Investment Insights - Rido Investment's chairman expressed optimism about the A-share market, suggesting it is in a historical opportunity for value reassessment, particularly favoring the entertainment and financial sectors [17]

Core Viewpoint - The article discusses the emergence of private equity firms engaging in creative projects, specifically the production of a short drama centered around futures trading, highlighting the challenges and uncertainties in the futures investment landscape [1] Group 1: Short Drama Production - Three private equity firms, Waying Investment, Shanhai Fund, and Shenhan Capital, have produced a short drama titled "Rebirth in the Millennium: My Revenge Path through Futures" [1] - The drama features a billionaire private equity boss who faces significant losses due to market volatility and personal tragedy, ultimately leading to a second chance in the year 2000 [1] Group 2: Performance of Private Equity Products - As of July 25, 2025, there are 603 futures and derivatives strategy products with a total scale of approximately 34.33 billion, with an average return of 8.73% this year [3] - Among these, 339 quantitative CTA products have an average return of 8.31%, while 156 subjective CTA products have an average return of 12.15% [3] Group 3: Top Performing Products - The top three futures and derivatives strategy products for the year are led by Fuhua Zixin's product, with a return of ***% [9] - In the category of private equity firms with a scale below 5 billion, the top three products are from Fuhua Zixin, Jingsheng Investment, and Ruixin Investment [10] Group 4: Recent Performance Trends - Over the past year, 573 products have shown an average return of 20.66%, with quantitative CTA products averaging 19.07% and subjective CTA products averaging 28.76% [9] - The leading products in this category are managed by Xuming Investment and Fuhua Zixin [10] Group 5: Long-Term Performance - Over the past three years, 345 products have an average return of 61.65%, with quantitative CTA products averaging 30.18% and subjective CTA products averaging 74.70% [14] - The top three products in this category are from Fuying Investment, Xuming Investment, and Ruixin Tiansuan [15]

Core Viewpoint - The pharmaceutical industry has experienced a significant rebound in 2023 after years of policy adjustments and market corrections, with a year-to-date increase of 37.42%, leading all sectors in performance [1]. Group 1: Investment Performance - The "Harmonious Huiyi Medical Innovation B Class" fund, managed by Harmony Huiyi's investment manager Shi Yue, was established during a downturn in the pharmaceutical sector and has achieved impressive returns since its inception [2]. - The fund's performance includes a significant return since its establishment on August 16, 2022, and a notable increase in 2023 [2]. Group 2: Manager Insights - Shi Yue, with 15 years of experience in the securities industry, emphasizes the pharmaceutical sector's resilience driven by demographic trends and healthcare needs [3][6]. - The investment strategy focuses on long-term investments in high-growth companies within the pharmaceutical sector, with a preference for companies in the growth and early maturity phases [6][10]. Group 3: Market Trends and Future Outlook - The pharmaceutical sector is characterized by its weak cyclicality and low correlation with macroeconomic factors, making it a stable investment choice [6]. - The current market dynamics show a strong focus on innovative drugs and medical devices, with a positive outlook for the sector's performance in the coming years [11][15]. - The recent rebound in the pharmaceutical sector is attributed to a re-evaluation of high-quality assets in China, with a focus on innovative drugs and medical devices [10][11]. Group 4: Investment Strategy - The investment approach involves a top-down selection of high-growth sub-industries and a focus on companies with strong growth potential [6][10]. - Shi Yue's strategy includes a global perspective, utilizing flexible allocation across A-shares, Hong Kong stocks, and U.S. stocks to capture diverse alpha opportunities [9][10]. - The emphasis is on identifying high-value, high-frequency consumption products within the pharmaceutical sector, particularly in oncology [12].

Core Viewpoint - The article highlights the significance of small and high-quality private equity fund managers in the industry, focusing on ZhiRuiXing Investment, which specializes in subjective long positions in stocks and has a strong track record in risk control and absolute returns [8][26]. Company Overview - ZhiRuiXing Investment was established in 2015, with a registered capital of 10 million. It is located in Shenzhen and has become a member of the Asset Management Association of China [8][9]. - The founder and core fund manager, Wang Zhongyuan, has 32 years of experience in the industry, including nearly 20 years of public performance records and has managed public funds exceeding 100 billion [8][12]. Development History - The company launched its first product in November 2015 and became an observation member of the China Fund Industry Association in May 2018. It received investments from Guotai Junan and CICC Wealth in 2019 and 2023, respectively [9][10]. - ZhiRuiXing's management scale surpassed 500 million in February 2024, marking its tenth anniversary in January 2025 [9]. Investment Philosophy & Strategies - The investment philosophy emphasizes risk control, aiming for absolute returns while maintaining a low drawdown. The strategy includes flexible and balanced asset allocation, focusing on both growth and value stocks [14][21]. - The company employs a top-down approach for macro position timing and style rotation, while also conducting bottom-up stock selection to identify "gray horse" stocks with growth potential and valuation appeal [16][17]. Core Team - The core team has over ten years of experience in public funds, securities firms, and private equity, ensuring a robust foundation for investment strategies [11]. Performance Metrics - ZhiRuiXing has achieved positive returns in 9 out of the last 10 years, with an annualized return of nearly 17%, successfully navigating multiple market cycles [22][24]. - The maximum historical drawdown of its products is only 18%, showcasing strong risk management capabilities [21]. Market Outlook - The company is optimistic about the Hong Kong stock market, which has seen nearly a 20% increase in major indices. It anticipates continued interest in core assets such as high-dividend stocks, new consumption, and AI-related sectors [26][28]. - The macroeconomic environment presents challenges, but the development of new industries, particularly in AI, is seen as a critical area for future investment opportunities [28].

Core Viewpoint - The article highlights the growing prominence of quantitative private equity funds, which have outperformed subjective funds in terms of absolute and excess returns, leading to an increase in the number of billion-yuan quantitative private equity firms [2][17]. Group 1: Market Overview - As of July 25, 2025, there are 90 billion-yuan private equity firms, with quantitative firms increasing to 44, while subjective firms decreased to 39, indicating a shift in market dynamics [2][8]. - The distribution of billion-yuan private equity firms is concentrated in major cities, with Shanghai leading at 39 firms, followed by Beijing with 24 and Shenzhen with 6 [8]. Group 2: Firm Changes - Three subjective private equity firms exited the billion-yuan club: Hongchou Investment, Suijiu Investment, and Heyuan Fund, while three new firms entered, including two quantitative firms: Qianyan Private Equity and Shanghai Boke Private Equity [4][5][6]. - The newly established Shanghai Boke Private Equity is noted for its young age, having been founded in July 2022, and aims to provide a comprehensive fund management platform [6][7]. Group 3: Performance Metrics - Among the billion-yuan private equity firms, 42 have shown positive returns this year, with the top three performers being Fusheng Asset, Qukou Investment, and Wenbo Investment [15][21]. - Quantitative private equity firms have significantly outperformed subjective firms this year, with average returns for quantitative firms being higher than those for subjective firms [17][21]. Group 4: Investment Strategies - The majority of billion-yuan private equity firms focus on stock investment strategies, totaling 69 firms, followed by multi-asset strategies with 12 firms and bond strategies with 6 firms [9][19]. - Wenbo Investment, established in 2014, utilizes a unique quantitative investment model that analyzes economic data to develop various investment strategies [19].

Core Insights - The global economy is undergoing profound changes, with emerging economies rising and major power dynamics at play, highlighting the importance of diversified asset allocation and cross-border investment [1] - Hong Kong, as a key financial hub connecting East and West, continues to attract global investors due to its mature financial ecosystem and unique position backed by mainland China [1] - The inaugural Hedge Fund and Family Office Awards will be held on August 22, 2025, in Hong Kong, organized by 排排网全球, aiming to integrate industry resources and facilitate high-level discussions on cross-border investment [1] Awards and Recognition - The awards will feature two main categories: the "Excellence Award" for outstanding institutions leading the industry and the "Emerging Award" to recognize promising new managers [2] - The selection process involves a combination of quantitative metrics and qualitative assessments by a global panel of experts, focusing on investment capabilities and future potential [2] Roundtable Discussions - Three in-depth roundtable forums will be held, covering strategies to navigate market volatility, the impact of AI on investment management, and the strategic allocation of family offices [3][4][5] - The first roundtable will discuss multi-dimensional investment strategies in the context of geopolitical conflicts and global market fluctuations [3] - The second roundtable will focus on the competitive landscape in Hong Kong, exploring how emerging managers can differentiate themselves and secure investor trust [4] - The third roundtable will address the evolution of family office direct investment trends and the role of Hong Kong resources in global strategic planning [5] 排排网全球 Overview - 排排网全球 is a key part of 排排网 Group's globalization strategy, dedicated to serving high-net-worth Chinese investors and providing a comprehensive financial information service platform [6][11] - The group has been active in the financial technology sector since its establishment in 2004, serving over 3 million high-net-worth clients with wealth management services [9][12] - The awards ceremony aims to create a platform for practical exchanges and collaborations in the cross-border investment sector, inviting industry professionals and media to explore new investment opportunities [6][12]

本文首发于公众号"私募排排网"。 （点击↑↑ 上图订阅专栏 ） 在2025上半年北京地区量化榜中，信弘天禾上半年以***%的收益夺冠 （ 点此看收益 ） 。 基金经理张华和章毅管理的"信弘征程2号B类 份额"上半年收益为***%，表现较为突出。 在2025半年度中证500指增产品榜中， 信弘天禾的"信弘中证500指数增强2号A类份额"，以***%的超额收益排名第一 ，上半年绝对收益 则为***%。 （ 点此看收益 ） 下面，就让我们一起深入了解信弘天禾。 （ 左右滑动下方图片看更多榜单 ） 编者按 在财富管理的大航海时代，私募基金以其灵活的策略、专业的团队和追求绝对收益的目标，吸引了越来越多高净值投资者的目光。然而，这个 行业也因其信息较少、不对称等特性，蒙上了一层神秘的面纱。策略如何运作？团队水平如何？短、中、长期业绩表现如何？风险控制究竟如 何……这些问题，往往是投资者在做出决策时，最难穿透的"迷雾"。正是基于此，私募排排网隆重推出 "深度 揭秘100家 私募" 栏目。为投资 者拨开云雾，提供真正有价值的深度洞察。 第三期我们将揭秘 百亿量化私募信弘天禾 ，信弘天禾在2025上半年的榜单中勇夺多个第一 。 ...